Humanwell Healthcare Group Co Ltd
SSE:600079
Net Margin
Humanwell Healthcare Group Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Humanwell Healthcare Group Co Ltd
SSE:600079
|
33.7B CNY |
8%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
683.1B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
357.9B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
193.7B CHF |
20%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
171.5B CHF |
23%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
155.3B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
196.4B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
-126%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
111.1B EUR |
13%
|
Humanwell Healthcare Group Co Ltd
Glance View
In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Humanwell Healthcare Group Co Ltd's most recent financial statements, the company has Net Margin of 7.7%.
You don't have any saved screeners yet